1.17
-0.01(-0.85%)
Currency In USD
| Previous Close | 1.18 |
| Open | 1.18 |
| Day High | 1.21 |
| Day Low | 1.1 |
| 52-Week High | 3.78 |
| 52-Week Low | 0.86 |
| Volume | 3M |
| Average Volume | 3.37M |
| Market Cap | 255.92M |
| PE | -0.96 |
| EPS | -1.22 |
| Moving Average 50 Days | 1.38 |
| Moving Average 200 Days | 2.09 |
| Change | -0.01 |
If you invested $1000 in Allogene Therapeutics, Inc. (ALLO) since IPO date, it would be worth $46.8 as of June 01, 2025 at a share price of $1.17. Whereas If you bought $1000 worth of Allogene Therapeutics, Inc. (ALLO) shares 5 years ago, it would be worth $23.91 as of June 01, 2025 at a share price of $1.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire Inc.
May 23, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease,
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
GlobeNewswire Inc.
May 22, 2025 9:17 PM GMT
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease,
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
GlobeNewswire Inc.
May 06, 2025 12:30 PM GMT
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the deve